Drugs Containing Excipient (Inactive Ingredient) HYDROXYPROPYL METHYLCELLULOSE

Branded drugs containing HYDROXYPROPYL METHYLCELLULOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	MUCINEX DM	guaifenesin and dextromethorphan hydrobromide	50090-1077	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	ELIQUIS	apixaban	50090-1436	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	MUCINEX	guaifenesin	50090-2301	HYDROXYPROPYL METHYLCELLULOSE

Generic drugs containing HYDROXYPROPYL METHYLCELLULOSE excipient

Company	Ingredient	NDC	Excipient
MARKSANS PHARMA LIMITED	loperamide hydrochloride tablets usp, 2mg	25000-001	HYDROXYPROPYL METHYLCELLULOSE
Camber Pharmaceuticals Inc	buprenorphine and naloxone	31722-479	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	indomethacin	50090-0055	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	amoxicillin	50090-0405	HYDROXYPROPYL METHYLCELLULOSE

Hydroxypropyl Methylcellulose Market Dynamics, Financial Trajectory, Regulation, and Patent Landscape

Last updated: August 18, 2026

Hydroxypropyl methylcellulose, also known as hypromellose or HPMC, is a mature pharmaceutical excipient with recurring demand from oral solid-dose medicines, controlled-release formulations, film coatings, ophthalmic products, and vegetarian capsules. Its commercial outlook is driven by generic-drug volume, modified-release development, capsule substitution, and regional pharmaceutical manufacturing capacity rather than by exclusivity.

HPMC has no meaningful Orange Book patent barrier. The core material is an established cellulose ether, while newer intellectual-property protection generally covers specific grades, manufacturing processes, capsule structures, coatings, or drug formulations. Supplier qualification, regulatory documentation, batch consistency, and manufacturing capacity are more important competitive barriers than basic composition patents.

What is hydroxypropyl methylcellulose used for in pharmaceuticals?

HPMC is a nonionic, water-soluble cellulose ether produced by chemically modifying cellulose with methoxy and hydroxypropoxy groups. Its performance depends on substitution levels, viscosity grade, particle size, hydration behavior, gel temperature, and molecular-weight distribution.

Pharmaceutical applications include:

Application	Function of HPMC	Commercial relevance
Tablet binding	Improves granule cohesion and tablet strength	Common in wet granulation and direct-compression systems
Film coating	Forms a clear, flexible film	Used in immediate-release tablets and taste masking
Controlled release	Creates a hydrated gel matrix	Major application in extended-release tablets
Capsule shells	Replaces gelatin	Supports vegetarian, religious, and low-moisture products
Ophthalmic products	Increases viscosity and residence time	Used in artificial tears and lubricating drops
Suspension systems	Provides viscosity and stabilization	Used in oral and topical formulations
Drug layering	Supports multiparticulates and pellets	Relevant to modified-release products
Hot-melt and specialty delivery	Provides matrix and film-forming properties	Smaller but technically valuable segment

HPMC is listed in the United States Pharmacopeia-National Formulary as hypromellose and is recognized in major pharmaceutical compendia, including the European Pharmacopoeia and Japanese Pharmacopoeia [1-3].

How large is the pharmaceutical HPMC market?

Published market estimates vary because analysts use different definitions. Some reports include food, construction, cosmetics, industrial cellulose ethers, HPMC capsules, and pharmaceutical-grade material in one category. Pharmaceutical HPMC alone is not separately reported in most public-company financial statements.

The defensible market conclusion is that pharmaceutical HPMC is a global, multi-hundred-million-dollar specialty-excipient segment within a larger cellulose-ether market. The broader HPMC and cellulose-ether markets are commonly estimated in the multi-billion-dollar range, but those figures include nonpharmaceutical applications such as construction materials, paints, personal care, and food.

The pharmaceutical segment has a more attractive product mix than commodity construction-grade HPMC because customers require:

• Compendial compliance.
• Tight viscosity and substitution specifications.
• Low bioburden and controlled impurities.
• Documentation supporting elemental impurities, residual solvents, and nitrosamine risk assessments.
• Technical support for dissolution and release profiles.
• Regulatory change-control management.
• Long-term supply continuity.

Pharmaceutical-grade revenue is therefore more closely linked to qualification status and grade selection than to raw-material volume alone.

What is driving HPMC market growth?

Generic and branded oral solid-dose manufacturing

Tablets remain the dominant pharmaceutical dosage form globally. HPMC is used across generic and branded products because it is compatible with common granulation, coating, and matrix-tablet processes. Growth in emerging pharmaceutical markets supports baseline volume, while mature markets generate recurring demand from large generic portfolios.

Controlled-release formulations

HPMC is one of the leading hydrophilic matrix polymers for extended-release tablets. Upon hydration, it forms a gel layer that regulates drug diffusion and erosion. Higher-viscosity grades generally support slower release, although performance depends on polymer concentration, drug solubility, tablet geometry, excipient composition, and manufacturing conditions.

Controlled-release applications generate higher technical switching costs. A customer changing HPMC grade may need to repeat formulation studies, dissolution comparisons, stability work, and regulatory documentation.

Vegetarian and specialty capsules

HPMC capsule shells gained share from gelatin in products marketed as vegetarian, vegan, halal, or kosher. HPMC also has lower moisture content than gelatin, which can benefit moisture-sensitive active ingredients.

Capsule demand is influenced by nutraceuticals as well as pharmaceuticals. This creates a larger addressable market but also exposes HPMC capsule suppliers to consumer-health cycles and pricing pressure.

Film coating and taste masking

Immediate-release tablets use HPMC as a film former because it provides transparent, flexible coatings and can be combined with plasticizers, pigments, and other coating ingredients. Colorcon, Ashland, Shin-Etsu, and other suppliers market HPMC-based coating systems and raw materials for this purpose.

Regional pharmaceutical expansion

India, China, Southeast Asia, Latin America, and the Middle East continue to expand oral solid-dose production. Regional growth supports demand for both standard and high-performance grades, but local procurement can increase price competition and qualification pressure.

Which companies supply pharmaceutical-grade HPMC?

The supplier base includes multinational chemical companies, specialist excipient manufacturers, and capsule producers. Key recognized suppliers and brands include:

Company	Relevant products or business exposure
Ashland	Benecel cellulose ethers and pharmaceutical excipient technologies
Shin-Etsu Chemical	Pharmacoat hypromellose grades and related pharmaceutical polymers
Lotte Fine Chemical	AnyCoat and cellulose-ether products
DuPont / Dow legacy businesses	METHOCEL cellulose-ether materials and pharmaceutical grades
Colorcon	HPMC-based coating systems and formulation support
JRS Pharma	Pharmaceutical excipient portfolio, including cellulose-based materials
Qualicaps	HPMC capsule manufacturing and capsule technologies
Lonza Capsules & Health Ingredients	HPMC capsule products and capsule manufacturing
Capsugel-related businesses	Vegetarian capsule platforms and delivery systems
Chinese and Indian manufacturers	Increasing supply of compendial HPMC and regional alternatives

Brand ownership and business structures can change because cellulose-ether and capsule businesses have experienced acquisitions, divestitures, and portfolio reorganizations. Procurement teams should verify the current legal manufacturer, site of manufacture, and quality agreement for each grade.

How does pharmaceutical HPMC pricing work?

HPMC pricing is determined by grade, viscosity, substitution profile, manufacturing location, order volume, qualification status, and technical support requirements.

Standard low- and medium-viscosity grades are more exposed to competition. High-viscosity grades, capsule-shell materials, specialty coating polymers, and products with extensive regulatory support command stronger pricing.

The main cost drivers are:

1. Refined cellulose and wood-pulp inputs.
2. Methyl chloride and propylene oxide.
3. Energy and chemical-processing costs.
4. Plant utilization and capacity availability.
5. Quality-control testing and batch-release requirements.
6. Freight, inventory, and regional warehousing.
7. Customer-specific documentation and change-control obligations.

Pricing typically follows a two-tier structure. Commodity-like grades experience competition from multiple Asian producers. Validated pharmaceutical grades maintain higher margins because replacement requires technical and regulatory work.

What is the financial trajectory for pharmaceutical HPMC?

The financial trajectory is likely to show steady volume growth, moderate value growth, and periodic margin volatility.

Base-case market trajectory

Period	Expected market condition
2024-2025	Normalization after freight, energy, and inventory disruptions; customers continue destocking selectively
2025-2027	Low- to mid-single-digit volume growth from generics, controlled release, and capsule conversion
2027-2030	Continued expansion in emerging pharmaceutical markets and specialty delivery systems
Long term	Stable demand with premiumization in high-performance grades and capsules

Revenue growth should exceed volume growth when suppliers shift customers toward higher-viscosity, specialty, or integrated coating and capsule systems. Commodity-grade price competition can produce the opposite effect.

Public companies generally do not disclose HPMC revenue as a separate line item. Ashland reports broader life-sciences and specialty-materials activities rather than standalone HPMC sales. Shin-Etsu and Lotte Fine Chemical also report cellulose-related activities within broader business segments. This limits direct peer comparison and makes industry pricing, capacity, and customer-qualification data more important than reported segment revenue alone [4-6].

Margin considerations

HPMC manufacturers with integrated production, global qualification, and differentiated grades have stronger margin protection than resellers or undifferentiated producers. Margin pressure can arise from:

• New Asian capacity.
• Lower freight rates.
• Customer inventory correction.
• Pulp and energy-cost declines being passed through to buyers.
• Generic-drug purchasing consolidation.
• Multi-sourcing by large pharmaceutical manufacturers.

The strongest financial exposure is held by suppliers selling validated, high-viscosity grades and capsule systems. The weakest exposure is held by suppliers competing primarily on standard-grade price.

What patents protect hydroxypropyl methylcellulose?

The basic HPMC material is not protected by a commercially meaningful, current composition patent. Its underlying chemistry and pharmaceutical use are established. Core patents associated with cellulose ether production and early pharmaceutical applications expired many years ago.

Current patent activity is concentrated in narrower categories:

HPMC manufacturing patents

These patents may cover:

• Cellulose activation and etherification conditions.
• Substitution-level control.
• Particle-size engineering.
• Purification and washing.
• Low-impurity production.
• High-viscosity or narrow-distribution grades.
• Drying and milling methods.

Such patents may create process advantages, but they generally do not prevent customers from using HPMC sourced from another manufacturer.

Formulation patents

A pharmaceutical company may patent a formulation containing HPMC, including:

• Specific drug-to-polymer ratios.
• Matrix-tablet architecture.
• Multi-layer tablets.
• Release profiles.
• Coating combinations.
• Granulation processes.
• Drug-polymer interactions.
• Abuse-deterrent or gastroretentive systems.

These patents protect the drug product or delivery system, not HPMC as a commodity excipient.

Capsule patents

HPMC capsule patents can cover shell composition, gelling systems, manufacturing conditions, shell strength, moisture control, and compatibility with fill materials. Capsule manufacturers may also protect machinery, sealing systems, and specialized capsule formats.

What is the Orange Book status of hydroxypropyl methylcellulose?

HPMC itself has no Orange Book listing because it is an excipient, not an FDA-approved active pharmaceutical ingredient. It has no standalone FDA new-drug exclusivity, no Paragraph IV challenge pathway, and no Hatch-Waxman patent term.

The FDA Inactive Ingredient Database identifies excipients used in approved drug products and provides route- and dosage-form information. Inclusion in the database does not create market exclusivity or patent protection [7].

A finished drug containing HPMC may have Orange Book-listed patents if the active ingredient, formulation, delivery system, or method of use is protected. Those patents belong to the finished drug product and are evaluated in the context of an abbreviated new drug application.

When does HPMC lose exclusivity?

HPMC does not have a single exclusivity-loss date. The core material is already off-patent.

Exclusivity risk occurs at the customer-product level:

• A controlled-release tablet may face generic entry after its formulation or method-of-use patents expire.
• An HPMC capsule may face competition when capsule-shell patents expire or when alternative shell technologies qualify.
• A supplier-specific manufacturing process may lose protection on its patent expiration date, without eliminating the supplier's commercial advantage.
• A formulation patent may expire later than the underlying HPMC technology.

This structure favors incumbent suppliers with validated manufacturing sites, but it prevents them from relying on a broad molecule-level monopoly.

Are there Paragraph IV challenges involving HPMC?

There is no conventional Paragraph IV challenge to HPMC as an excipient. Paragraph IV litigation applies to ANDA applicants challenging patents listed for approved drug products in the Orange Book.

HPMC can appear as an ingredient in a drug product involved in Paragraph IV litigation, but the dispute typically concerns the active ingredient, release mechanism, dosage form, or method of treatment. The presence of HPMC does not independently create an ANDA barrier.

What regulatory requirements apply to pharmaceutical HPMC?

Pharmaceutical HPMC suppliers must support multiple regulatory and quality requirements:

• USP-NF, European Pharmacopoeia, and Japanese Pharmacopoeia compliance.
• Good Manufacturing Practice controls appropriate for excipients.
• Supplier qualification and audit readiness.
• Change-control notification.
• Residual-solvent monitoring.
• Elemental-impurity assessment.
• Microbial and bioburden controls.
• Nitrosamine-risk assessment where relevant.
• Extractables and leachables data for capsule and packaging applications.
• Stability and storage data.
• Traceability of cellulose and chemical inputs.

The International Pharmaceutical Excipients Council's Good Manufacturing Practices Guide for Pharmaceutical Excipients is a major industry reference for excipient quality systems [8]. The European Medicines Agency also expects manufacturers to manage excipient quality and risk within pharmaceutical quality systems [9].

Regulatory agencies do not generally approve HPMC through the same application pathway used for active ingredients. Instead, the finished-drug sponsor is responsible for demonstrating that the excipient is suitable for its intended use.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more important than basic patent barriers.

A new supplier must demonstrate:

• Reproducible substitution chemistry.
• Consistent viscosity across batches.
• Reliable hydration and gel formation.
• Low contamination and impurity levels.
• Global compendial compliance.
• Adequate capacity and business continuity.
• Technical support for formulation transfer.
• Regulatory documentation in multiple jurisdictions.

A customer may qualify a second supplier to reduce concentration risk, but switching can affect dissolution, coating performance, tablet hardness, capsule brittleness, and stability. These technical effects create practical retention even when no patent blocks substitution.

The strongest barriers are therefore operational:

1. Validated production sites.
2. Long customer histories.
3. Multi-region supply.
4. Proprietary grade specifications.
5. Formulation-development expertise.
6. Regulatory change-control performance.

How does HPMC compare with competing excipients?

Excipient	Main advantage	Main limitation
HPMC	Broad compatibility, controlled release, film formation, vegetarian capsules	Can require formulation optimization for hydration and release
HPC	Strong film formation and solubility	Less dominant in some controlled-release matrix applications
Povidone	Strong binder and solubilizer	Less suitable as the sole extended-release matrix polymer
Ethylcellulose	Water-insoluble barrier and sustained release	Requires different processing and coating strategies
Sodium carboxymethylcellulose	Swelling and viscosity	Ionic behavior can create compatibility issues
Gelatin	Established capsule technology and mechanical performance	Animal origin and higher moisture sensitivity
HPMC acetate succinate	Enteric and amorphous-solid-dispersion applications	Higher cost and more specialized processing

HPMC's competitive position is strongest where one polymer can support several functions within the same product platform.

What generic entry risks exist for pharmaceutical HPMC suppliers?

Generic entry risk is moderate for standard grades and lower for highly qualified specialty grades. The major risks are substitution by:

• Lower-cost regional suppliers.
• Alternative cellulose ethers.
• Direct customer qualification of dual sources.
• HPMC-based premixes from coating suppliers.
• Non-HPMC capsule materials.
• Reformulation around supply constraints.

Customers may tolerate a price premium for validated grades when switching would trigger dissolution studies or regulatory submissions. That premium narrows when regulators accept multiple suppliers and the product has simple immediate-release performance.

What licensing deals and partnerships affect HPMC?

Public licensing activity is limited because HPMC is a mature excipient rather than a proprietary active technology. Commercial relationships generally take the form of:

• Long-term supply agreements.
• Private-label manufacturing.
• Capsule-production partnerships.
• Technology transfers.
• Coating-system collaborations.
• Regional distribution arrangements.
• Joint development of controlled-release platforms.

The absence of widely publicized HPMC licensing transactions indicates that competitive value is usually captured through manufacturing scale, customer qualification, and integrated technical service rather than royalty-bearing molecule licenses.

What patent litigation affects HPMC?

HPMC does not generate a standalone patent-litigation market comparable to branded pharmaceuticals. Litigation exposure arises indirectly through finished products using HPMC in:

• Extended-release tablets.
• Abuse-deterrent dosage forms.
• Enteric or delayed-release products.
• Multiparticulate delivery systems.
• Capsule-based drug products.
• Ophthalmic formulations.

A supplier can become relevant to litigation through discovery, technical evidence, or indemnification provisions in a customer contract. The supplier's own HPMC patent estate is unlikely to determine whether a generic drug launches unless the dispute concerns a specific proprietary grade or delivery system.

Key Takeaways

• HPMC is a mature, globally established pharmaceutical excipient sold under names including hypromellose.
• Its main pharmaceutical applications are controlled-release matrices, tablet coatings, binders, ophthalmic products, and vegetarian capsules.
• The segment should experience steady low- to mid-single-digit volume growth, with stronger value growth in specialty grades and integrated capsule or coating systems.
• The core HPMC composition is off-patent and has no standalone Orange Book exclusivity.
• Paragraph IV litigation does not apply to HPMC itself.
• Finished drugs containing HPMC can have Orange Book patents covering formulations, release profiles, delivery systems, or methods of use.
• Supplier qualification, batch consistency, regulatory documentation, and capacity are the principal commercial barriers.
• Standard-grade pricing faces pressure from Asian capacity and multi-sourcing.
• Specialty-grade suppliers have better margin protection because switching can affect dissolution, stability, and regulatory filings.
• Public companies rarely disclose HPMC revenue separately, so direct financial benchmarking remains limited.

FAQs

Is hydroxypropyl methylcellulose the same as hypromellose?

Yes. Hypromellose is the official pharmaceutical name commonly used for hydroxypropyl methylcellulose, abbreviated HPMC.

Is HPMC considered an active pharmaceutical ingredient?

No. HPMC is generally an inactive pharmaceutical ingredient, or excipient. It provides physical and functional properties to the dosage form.

Can pharmaceutical companies switch HPMC suppliers without regulatory work?

Not always. A switch may require comparative testing, formulation assessment, dissolution testing, stability data, and regulatory change documentation, particularly for controlled-release products.

Does HPMC qualify as a high-margin pharmaceutical material?

Specialty pharmaceutical HPMC can support higher margins than industrial grades because of qualification, documentation, and technical-service requirements. Standard grades face stronger price competition.

Is HPMC suitable for biologic drug delivery?

HPMC is used mainly in oral, topical, ophthalmic, and capsule applications. Its role in biologics is more limited because many biologic products require parenteral delivery and specialized excipient systems.

References

1. United States Pharmacopeial Convention. (2024). Hypromellose. In United States Pharmacopeia and National Formulary (USP-NF).
2. European Directorate for the Quality of Medicines & HealthCare. (2024). Hypromellose. In European Pharmacopoeia.
3. Pharmaceutical and Medical Device Agency. (2024). Japanese Pharmacopoeia. Ministry of Health, Labour and Welfare, Japan.
4. Ashland Global Holdings Inc. (2023). Annual report for fiscal year 2023.
5. Shin-Etsu Chemical Co., Ltd. (2024). Annual report and integrated report.
6. Lotte Fine Chemical Co., Ltd. (2024). Annual report.
7. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
8. International Pharmaceutical Excipients Council Federation. (2017). Good manufacturing practices guide for pharmaceutical excipients.
9. European Medicines Agency. (2015). Guideline on the assessment of the quality of excipients in medicinal products.